quadgram

This is a table of type quadgram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

quadgram	frequency
in the united states	500
severe acute respiratory syndrome	415
safety and immunogenicity of	237
for the development of	220
acute respiratory syndrome coronavirus	201
in the case of	190
in the development of	174
the development of a	165
middle east respiratory syndrome	147
in the absence of	146
one of the most	141
as well as the	141
has been shown to	138
as a result of	130
and cellular immune responses	129
on the other hand	125
is one of the	125
in the context of	121
in the presence of	113
the immune response to	112
humoral and cellular immune	111
the development of vaccines	110
and immunogenicity of a	110
modified vaccinia virus ankara	108
the world health organization	107
cd and cd t	107
on the surface of	107
to the development of	105
of the immune system	105
of the immune response	104
have been shown to	102
hepatitis b surface antigen	100
at the same time	98
centers for disease control	96
at the time of	93
was found to be	92
it is important to	90
been shown to be	87
of severe acute respiratory	87
can be used to	87
east respiratory syndrome coronavirus	86
for disease control and	86
disease control and prevention	85
a single dose of	80
on the basis of	79
cd t cell responses	78
for the prevention of	78
in vitro and in	73
for the treatment of	72
for the production of	72
an important role in	71
safety and efficacy of	71
vitro and in vivo	69
food and drug administration	69
human immunodeficiency virus type	68
h n and h	67
n and h n	67
of influenza a virus	65
in addition to the	65
h n influenza virus	65
and cd t cells	65
advisory committee on immunization	64
the end of the	64
committee on immunization practices	64
immunogenicity and safety of	63
in the form of	63
the development of new	63
to display the preprint	61
at the site of	61
a license to display	61
granted medrxiv a license	61
has granted medrxiv a	61
who has granted medrxiv	61
a wide range of	61
license to display the	61
display the preprint in	61
is the author funder	61
medrxiv a license to	61
studies have shown that	60
development of a vaccine	60
in the united kingdom	60
and humoral immune responses	60
influenza a h n	60
copyright holder for this	59
the copyright holder for	59
phase i clinical trial	59
a protective immune response	58
porcine reproductive and respiratory	57
reproductive and respiratory syndrome	57
u r n a	56
r n a l	56
j o u r	56
vaccines have been developed	56
development of vaccines against	56
o u r n	56
p r o o	55
cellular and humoral immune	55
n a l p	55
at the injection site	55
were found to be	55
a l p r	55
l p r e	55
r o o f	55
the united states and	54
the advisory committee on	54
in balb c mice	54
in the production of	53
both humoral and cellular	53
haemophilus influenzae type b	52
innate and adaptive immune	52
at the end of	52
the surface of the	51
the innate immune system	51
immune response to the	51
influenza a and b	50
the safety and immunogenicity	50
a wide variety of	49
of respiratory syncytial virus	49
have been used to	48
this version posted october	48
and immunogenicity of an	48
and cd t cell	47
and respiratory syndrome virus	47
specific cd t cells	47
for the induction of	47
parts of the world	47
have the potential to	47
h n influenza viruses	47
the use of a	47
the efficacy of the	46
on the use of	46
in a mouse model	46
is likely to be	46
is based on the	46
efficacy and safety of	46
in the field of	45
vaccine in healthy adults	45
of the vaccine construct	45
allergy and infectious diseases	45
of the advisory committee	45
the immunogenicity of the	45
the development of the	45
of allergy and infectious	44
as a vaccine vector	44
national institutes of health	43
be used as a	43
the nature of the	43
in the respiratory tract	43
and the development of	42
play an important role	42
it has been shown	42
has been used to	42
of a dna vaccine	42
immunization of mice with	42
foot and mouth disease	42
a large number of	42
the centers for disease	42
porcine epidemic diarrhea virus	41
prevention and control of	41
the upper respiratory tract	41
h n avian influenza	41
infants and young children	41
h n influenza vaccine	41
it is likely that	40
for the delivery of	40
as part of the	40
has the potential to	40
to the use of	40
as well as in	40
health and human services	40
the development of an	40
of health and human	40
in the treatment of	40
highly pathogenic avian influenza	40
rift valley fever virus	40
recommendations of the advisory	40
play a role in	39
systematic review and meta	39
immunogenicity and protective efficacy	39
of morbidity and mortality	39
immune responses induced by	39
can be used as	39
and immunogenicity of the	38
national institute of allergy	38
and the use of	38
of the s protein	38
institute of allergy and	38
in a number of	38
the safety and efficacy	38
of cd t cells	38
with the development of	38
with the use of	38
it is possible to	38
the central nervous system	38
the beginning of the	38
preprint this version posted	37
a phase i clinical	37
an increase in the	37
in the number of	37
a systematic review and	37
the preprint in perpetuity	37
a review of the	37
this preprint this version	37
for this preprint this	37
a universal influenza vaccine	37
have been used for	37
to be safe and	37
in a phase i	37
humoral and cellular immunity	37
to develop a vaccine	37
holder for this preprint	37
can be used for	36
the severe acute respiratory	36
no conflict of interest	36
was shown to be	36
in the control of	36
it is clear that	36
department of health and	36
are likely to be	36
is protected by copyright	36
to the immune system	36
this article is protected	36
article is protected by	36
in a variety of	35
for the first time	35
with severe acute respiratory	35
mucosal and systemic immune	35
can be used in	35
not certified by peer	35
the development of effective	35
a major cause of	35
as well as a	35
which was not certified	35
live attenuated influenza vaccine	35
in response to the	35
vaccine based on the	35
certified by peer review	35
and safety of a	35
was not certified by	35
development of new vaccines	35
is made available under	34
of the h n	34
of the influenza virus	34
that can be used	34
available under a is	34
a is the author	34
under a is the	34
a safe and effective	34
made available under a	34
of human immunodeficiency virus	34
of the innate immune	34
the use of the	34
immune responses in the	34
it is made available	34
the ability of the	34
mechanism of action of	34
t cell responses in	34
in the face of	33
of immune responses to	33
license it is made	33
it is possible that	33
by the use of	33
a strong immune response	33
cd t cells in	33
have been used in	33
approved for use in	33
efficacy of the vaccine	33
the immune system to	33
respiratory syncytial virus infection	33
have been used as	33
it has been suggested	33
international license it is	33
are more likely to	33
the hepatitis b virus	32
the introduction of the	32
of a vaccine against	32
for use in the	32
immunogenicity of a recombinant	32
has been associated with	32
and systemic immune responses	32
and adaptive immune responses	32
acute respiratory distress syndrome	32
the efficacy of a	32
have been associated with	32
t cell responses to	32
have the ability to	32
has been shown that	32
protective immunity in mice	32
a result of the	31
in the early s	31
vaccines against infectious diseases	31
can be found in	31
has been suggested that	31
in the near future	31
immune responses in mice	31
morbidity and mortality in	31
at a dose of	31
in the present study	30
a broad range of	30
as one of the	30
of the vaccine in	30
cellular immune responses in	30
cd t cell response	30
to be associated with	30
and protective efficacy of	30
prevention and treatment of	30
children younger than years	30
the quality of the	30
for the expression of	30
the authors declare no	30
coalition for epidemic preparedness	30
the national institute of	30
of the safety and	29
in the prevention of	29
against respiratory syncytial virus	29
the need for a	29
the immune system and	29
highly pathogenic h n	29
both cellular and humoral	29
to weeks of age	29
licensed for use in	29
levels of neutralizing antibodies	29
for the use of	29
there is a need	29
the protective efficacy of	29
the mucosal immune system	29
venezuelan equine encephalitis virus	29
respiratory syndrome coronavirus spike	29
of h n influenza	29
have been made to	29
recombinant newcastle disease virus	29
and t cell responses	29
it was found that	29
with the exception of	28
of hepatitis b surface	28
adverse events associated with	28
under the control of	28
it should be noted	28
on the development of	28
the mechanism of action	28
peripheral blood mononuclear cells	28
progress has been made	28
at weeks of age	28
is considered to be	28
the expression of the	28
the development of novel	28
with respect to the	28
can also be used	28
the magnitude of the	28
through the use of	28
a high level of	28
as compared to the	28
a better understanding of	28
will need to be	28
of hepatitis b virus	28
there is an urgent	28
it is estimated that	28
b and t cell	28
a randomized controlled trial	28
a number of studies	28
been shown to induce	27
is an urgent need	27
the rational design of	27
at the beginning of	27
the role of the	27
to be able to	27
this is the first	27
influenza vaccine in the	27
the humoral immune response	27
immune response in mice	27
in the developing world	27
immune response against the	27
similar to that of	27
the h n pandemic	27
it was shown that	27
it is difficult to	27
of the virus and	27
could be used to	27
for the detection of	27
to ensure that the	27
have been tested in	26
it has been reported	26
to years of age	26
safe and immunogenic in	26
of the most important	26
to the presence of	26
the host immune system	26
the h n influenza	26
as well as to	26
have been developed to	26
to the site of	26
immunogenicity and efficacy of	26
has been reported that	26
that need to be	26
the s protein of	26
one of the major	26
to be effective in	26
and the risk of	26
specific cd and cd	26
under years of age	26
with a single dose	26
short period of time	26
the innate immune response	26
the spread of the	26
in the human population	25
has been used for	25
has yet to be	25
the safety of the	25
the presence of maternal	25
reduce the risk of	25
infectious diseases of the	25
of age or older	25
and respiratory syncytial virus	25
a vaccine based on	25
than years of age	25
the authors declare that	25
s protein of sars	25
in the uk and	25
as a means of	25
induction of protective immunity	25
by the world health	25
the use of vaccines	25
important role in the	25
and efficacy of a	25
a member of the	25
to the fact that	25
the daily risk of	25
the absence of a	25
the fact that the	25
the host immune response	25
the results of the	25
the lower respiratory tract	25
an increased risk of	25
should be noted that	24
the induction of a	24
of a vaccine for	24
have been found to	24
is the most common	24
in infants and young	24
the site of injection	24
bovine viral diarrhea virus	24
no reuse allowed without	24
protective immune responses against	24
in the late s	24
cholera toxin b subunit	24
over the past decade	24
for use in humans	24
the case of the	24
recent advances in the	24
classical swine fever virus	24
the united states in	24
plays an important role	24
used as a vaccine	24
the adaptive immune response	24
vaccine research and development	24
the context of the	24
to be the most	24
the causative agent of	24
of the virus in	24
to be used as	24
is thought to be	24
a major role in	24
reuse allowed without permission	24
influenza a virus infection	24
for respiratory syncytial virus	24
a recombinant adenovirus type	24
there is no evidence	24
a public health emergency	24
and mucosal immune responses	24
phase i clinical trials	24
by the immune system	24
human respiratory syncytial virus	23
the current recommendation is	23
spread of the virus	23
humoral and cellular responses	23
in the event of	23
years of age and	23
of middle east respiratory	23
at high risk of	23
in the use of	23
will be needed to	23
with the aid of	23
to be used in	23
for the control of	23
of a new vaccine	23
shown to be effective	23
tested in clinical trials	23
immune response in the	23
are summarized in table	23
presence or absence of	23
a significant increase in	23
the most widely used	23
in dogs and cats	23
b surface antigen in	23
pathogenic avian influenza virus	23
a high degree of	23
over years of age	23
as shown in fig	23
from person to person	23
of the vaccine was	23
has not yet been	23
vaccine based on a	23
and protective immunity in	23
should be able to	23
can be achieved by	23
pandemic h n influenza	23
the middle east respiratory	23
phase i ii clinical	23
for the generation of	23
this this version posted	22
in a murine model	22
years old or older	22
heat and rnase treated	22
a key role in	22
the heat and rnase	22
in the copyright holder	22
has led to the	22
of a recombinant adenovirus	22
the s and s	22
vaccine safety and immunogenicity	22
would like to thank	22
by the end of	22
the use of adjuvants	22
led to the development	22
of the efficacy of	22
in the design of	22
holder for this this	22
the activation of the	22
immune correlates of protection	22
the vast majority of	22
innate and adaptive immunity	22
in an effort to	22
despite the fact that	22
and h n influenza	22
in the pathogenesis of	22
or in combination with	22
the global burden of	22
for the presence of	22
enhance the immune response	22
h n influenza a	22
have been developed and	22
may be due to	22
with the help of	22
to participate in a	22
enhance the immunogenicity of	22
the national institutes of	22
have not yet been	22
in the s and	22
of newcastle disease virus	22
recombinant vesicular stomatitis virus	22
immune responses to a	22
cellular and humoral responses	22
it is necessary to	22
for this this version	22
preprint in the copyright	22
the presence or absence	22
of influenza a viruses	22
the preprint in the	22
both cd and cd	22
us food and drug	22
the structure of the	21
are shown in table	21
the h n virus	21
to cd t cells	21
more likely to be	21
development of vaccines for	21
in contrast to the	21
for epidemic preparedness innovations	21
presence of maternal antibodies	21
as part of a	21
the immune response against	21
respiratory syndrome coronavirus vaccine	21
systemic and mucosal immune	21
cellular immune responses to	21
a dna vaccine encoding	21
research and development of	21
it has also been	21
for the identification of	21
as well as other	21
outbreak in west africa	21
that they have no	21
the respiratory tract of	21
of a vaccine is	21
of the united states	21
cd t cells and	21
the size of the	21
declare no conflict of	21
protective immune response in	21
dna vaccines have been	21
in mice immunized with	21
have been reported in	21
have been reported to	21
virus as a vaccine	21
mechanisms of action of	21
response to the vaccine	21
a short period of	21
safe and effective vaccines	21
with the potential to	21
influenza virus infection in	21
authors declare no conflict	21
is due to the	21
the emergence of new	21
the most commonly used	21
the presence of the	21
the length of the	20
the spike protein of	20
the immune response of	20
disease prevention and control	20
the rest of the	20
of a novel coronavirus	20
t and b cells	20
at the university of	20
be due to the	20
feline infectious peritonitis virus	20
could be used as	20
adjuvanted h n vaccine	20
an overview of the	20
by the presence of	20
has been made in	20
hepatitis a and b	20
a phase clinical trial	20
also been shown to	20
during the course of	20
for the evaluation of	20
the importance of the	20
was approved by the	20
the vaccine and the	20
cellular and humoral immunity	20
type of immune response	20
children under years of	20
and weeks of age	20
in many parts of	20
of the hepatitis b	20
immunogenicity of an inactivated	20
infectious bursal disease virus	20
as is the case	20
is associated with the	20
and mouth disease virus	20
global vaccine action plan	20
in infants and children	20
of cd and cd	20
has also been shown	20
were more likely to	20
t cells in the	20
the dog and cat	20
the majority of the	20
delivery of dna vaccines	20
as a source of	20
immune response induced by	20
alone or in combination	20
the emergence of a	20
may need to be	20
induction of immune responses	20
the immune system of	20
all over the world	20
in the induction of	20
and the role of	20
and years of age	20
immune responses to vaccines	20
in adolescents and adults	20
respiratory syncytial virus disease	20
of the disease and	20
of live attenuated vaccines	19
has been reported to	19
better understanding of the	19
hepatitis b virus core	19
it is essential to	19
herpes simplex virus type	19
it has been demonstrated	19
a vaccine against the	19
authors declare that they	19
with modified vaccinia virus	19
is a need to	19
to the lack of	19
development of a universal	19
vaccine safety and efficacy	19
spike protein of sars	19
at months of age	19
it was observed that	19
of the vaccine and	19
in the nasal cavity	19
of the viral genome	19
diseases of the dog	19
and the united states	19
a new generation of	19
the american academy of	19
to provide protection against	19
spread of the disease	19
and the lack of	19
major histocompatibility complex class	19
in the upper respiratory	19
h n influenza pandemic	19
and efficacy of the	19
one of the main	19
for the prediction of	19
of the dog and	19
the control of the	19
a critical role in	19
the coalition for epidemic	19
the immune epitope database	19
the antibody response to	19
vaccines that have been	19
there is also a	19
of the spike protein	19
to the surface of	19
one of the first	19
the use of live	19
the potential to be	19
to the induction of	19
the leading cause of	19
the genome of the	19
after the introduction of	19
as shown in figure	19
of the virus to	19
development of a new	19
patients with severe acute	19
n avian influenza virus	19
live attenuated influenza vaccines	19
phase i trial of	18
protection against challenge with	18
the adjuvant effect of	18
recombinant modified vaccinia virus	18
in the course of	18
adjuvants and delivery systems	18
of an inactivated vaccine	18
is the use of	18
it is known that	18
effectiveness of the vaccine	18
as a public health	18
protective efficacy of a	18
the innate and adaptive	18
chronic obstructive pulmonary disease	18
in human clinical trials	18
of ebola virus disease	18
are considered to be	18
is based on a	18
after a single dose	18
use of the vaccine	18
in the incidence of	18
the first year of	18
with the aim of	18
inactivated influenza vaccine in	18
been used as a	18
been found to be	18
vaccines for use in	18
by the fact that	18
to the identification of	18
specific t cell responses	18
immune responses in humans	18
to the emergence of	18
the development of more	18
declare that they have	18
of influenza a and	18
high levels of neutralizing	18
for more than years	18
have been developed for	18
in children younger than	18
h n influenza in	18
memory cd t cells	18
are included in the	18
immunogenicity of the vaccine	18
for the prevention and	18
has led to a	18
for a variety of	18
prevention of infectious diseases	18
safe and effective vaccine	18
vaccine has been shown	18
of the disease in	18
number of studies have	18
can be applied to	18
phase iii clinical trial	18
the ability to induce	18
the number of cases	18
that there is no	18
weeks of age and	18
in accordance with the	18
the vaccine construct was	18
of action of adjuvants	18
for vaccine development and	18
vaccine development has been	18
will have to be	18
the duration of the	18
respiratory syncytial virus vaccine	18
with a dna vaccine	18
fraction of people using	18
the stability of the	18
that the vaccine is	18
the introduction of a	18
and characterization of a	18
due to the lack	18
a second dose of	18
of the vaccine virus	18
for a long time	18
of influenza vaccine in	18
as soon as possible	18
the vaccine to be	18
specific cd t cell	18
the immune response in	18
vaccine for the prevention	17
has also been used	17
the receptor binding domain	17
at the level of	17
it is thought that	17
was observed in the	17
as a vaccine adjuvant	17
humoral immune response to	17
the us food and	17
a dna vaccine induces	17
is no evidence that	17
protective immune response against	17
by a variety of	17
be used for the	17
a recombinant newcastle disease	17
immune response that is	17
of the antigen and	17
response to influenza vaccination	17
antibodies directed against the	17
when compared to the	17
produced in insect cells	17
there has been a	17
is estimated to be	17
neutralization and protective immunity	17
adverse event reporting system	17
current recommendation is to	17
the rabies virus glycoprotein	17
in the past years	17
the impact of the	17
a reduction in the	17
for severe acute respiratory	17
a live attenuated vaccine	17
for the design of	17
the effectiveness of the	17
induces sars coronavirus neutralization	17
is important to note	17
important to note that	17
our understanding of the	17
against homologous and heterologous	17
efficacy and effectiveness of	17
have been evaluated in	17
in children and adults	17
immune response to vaccination	17
on the immune response	17
against hepatitis b virus	17
against severe acute respiratory	17
the characteristics of the	17
has been demonstrated that	17
a novel coronavirus from	17
phase iii clinical trials	17
approved by the fda	17
a phase i ii	17
be included in the	17
the food and drug	17
coronavirus neutralization and protective	17
of a variety of	17
of high levels of	17
of safe and effective	17
the presence of a	17
the us department of	17
national vaccine advisory committee	17
a vaccine vector for	17
of neutralizing antibodies and	17
the use of this	17
this type of vaccine	17
of the respiratory tract	17
of a universal influenza	17
in the presence or	17
vaccine against hepatitis b	17
dna vaccine induces sars	17
is related to the	17
protection against influenza virus	17
the basis of the	17
the use of viral	17
sars coronavirus neutralization and	17
a phase i trial	17
an understanding of the	17
the results showed that	17
has been found to	17
to evaluate the safety	17
an immune response that	17
vaccine induces sars coronavirus	17
a h n virus	17
the treatment of influenza	17
safe and well tolerated	17
and the presence of	17
the immune system in	17
the pandemic h n	16
that there is a	16
a phase i study	16
studies have demonstrated that	16
the response to the	16
a variety of infectious	16
a crucial role in	16
in combination with a	16
the use of an	16
of the live attenuated	16
to assess the safety	16
of the host immune	16
of cd t cell	16
has been observed in	16
bill melinda gates foundation	16
for a number of	16
evaluation of the safety	16
to the production of	16
of yellow fever virus	16
of protective immunity against	16
and the potential for	16
in the gastrointestinal tract	16
to induce protective immunity	16
has been attributed to	16
adults in the united	16
transmission of the virus	16
have also been used	16
the vaccine should be	16
of west nile virus	16
human immunodefi ciency virus	16
in patients with severe	16
the draining lymph nodes	16
is safe and immunogenic	16
many parts of the	16
aged years or older	16
the basis for the	16
and safety of the	16
review of the literature	16
the absence of any	16
newcastle disease virus expressing	16
expressed on the surface	16
is responsible for the	16
on the cell surface	16
mucosal and systemic immunity	16
the mhc class i	16
of feline infectious peritonitis	16
an increasing number of	16
it is expected that	16
be attributed to the	16
a limited number of	16
phase ii clinical trial	16
first year of life	16
is caused by the	16
regions of the world	16
be found in the	16
american academy of pediatrics	16
of the antibody response	16
the immune responses to	16
both innate and adaptive	16
against influenza a virus	16
of neutralizing antibodies in	16
in healthy adults aged	16
h n pandemic influenza	16
over a period of	16
included in the vaccine	16
cause of morbidity and	16
aged years and older	16
of the use of	16
used in combination with	16
the european medicines agency	16
with regard to the	16
of the mmr vaccine	16
the human immune system	16
vaccines have also been	16
in the elderly and	16
have shown that the	16
the risk of disease	16
trial safety and immunogenicity	16
spring viremia of carp	16
and the ability to	16
is believed to be	16
the lack of a	16
the design of a	16
the injection site and	16
areas of the world	16
the number of doses	16
in children under years	16
in the formation of	16
play a key role	16
the site of infection	16
in a study by	16
a broad spectrum of	16
development of an effective	16
against influenza virus infection	16
vaccines based on the	16
it is hoped that	16
and the number of	16
licensed in the united	16
a systematic review of	16
an urgent need for	16
to that of the	16
associated with the use	16
the prevention and treatment	16
an urgent need to	16
of the adaptive immune	16
the case of sars	16
syndrome coronavirus spike protein	16
a role in the	16
in this age group	15
were used for the	15
as a function of	15
the vaccine has been	15
specific humoral and cellular	15
vaccine adverse event reporting	15
of the effectiveness of	15
to enhance the immunogenicity	15
contact with the infected	15
regard to jurisdictional claims	15
and a number of	15
will depend on the	15
the clinical development of	15
of antibody responses to	15
to influenza vaccination in	15
in comparison to the	15
vaccination in the elderly	15
of rift valley fever	15
can be produced in	15
both systemic and mucosal	15
the event of a	15
than weeks of age	15
against a lethal challenge	15
published maps and institutional	15
a significant role in	15
a phase iii trial	15
associated with the development	15
the production of a	15
increase the risk of	15
remains neutral with regard	15
of immune responses by	15
has been used in	15
to evaluate the efficacy	15
cellular immune responses against	15
the delivery of dna	15
and protective efficacy in	15
at room temperature for	15
been used for the	15
of a foreign gene	15
the protein of interest	15
for their ability to	15
ministry of health of	15
on the role of	15
the route of administration	15
the antigenicity of the	15
the efficacy of influenza	15
in order to develop	15
syncytial virus infection in	15
may be used to	15
by the addition of	15
seasonal and pandemic influenza	15
into the host cell	15
induces protective immunity against	15
safety and immunogenicity study	15
even in the presence	15
claims in published maps	15
against a variety of	15
is caused by a	15
t cell and b	15
phase i and ii	15
of dna vaccines is	15
the potential to cause	15
the uk and us	15
and b cell epitopes	15
and the need for	15
jurisdictional claims in published	15
years of age or	15
has been demonstrated in	15
in combination with other	15
has also been reported	15
pan american health organization	15
of immune responses in	15
is a major cause	15
the identification of the	15
neutral with regard to	15
avian influenza a virus	15
vaccines against h n	15
to jurisdictional claims in	15
the immune response and	15
at high risk for	15
t cell responses and	15
in the general population	15
to be included in	15
protective immunity against influenza	15
maps and institutional affiliations	15
prediction of protective antigens	15
immune response to influenza	15
springer nature remains neutral	15
republic of the congo	15
serum institute of india	15
the creative commons attribution	15
over the past years	15
as a delivery system	15
can be divided into	15
and immunogenicity study of	15
are one of the	15
in the short term	15
in response to a	15
the adaptive immune system	15
the generation of a	15
the efficacy of this	15
nature remains neutral with	15
from patients with pneumonia	15
of the creative commons	15
of adaptive immune responses	15
of patients infected with	15
with regard to jurisdictional	15
a vaccine to prevent	15
shown to be safe	15
between the vaccine and	15
cytotoxic t cell responses	15
these results suggest that	15
of health of the	15
cellular immune responses and	15
against h n influenza	15
democratic republic of the	15
the immunogenicity of dna	15
in the usa and	15
of dogs and cats	15
of vaccines and vaccination	15
development and evaluation of	15
the fd c act	15
of mice with a	15
vaccines to protect against	15
newcastle disease virus vaccine	15
in published maps and	15
first licensed dengue vaccine	15
spring viraemia of carp	15
is associated with a	15
to be a major	15
is not recommended for	15
in the process of	15
induce the production of	15
in the lungs of	14
respiratory tract disease in	14
of the development of	14
distributed under the terms	14
vaccines are based on	14
also be used to	14
has the ability to	14
the immune response induced	14
as an adjuvant in	14
tertiary structure of the	14
isolation and characterization of	14
of herpes simplex virus	14
the respiratory syncytial virus	14
shown to be a	14
elicit an immune response	14
european centre for disease	14
the severity of the	14
is dependent on the	14
the research and development	14
the risks associated with	14
cell and b cell	14
were collected from the	14
the ministry of health	14
the start of the	14
of the th century	14
immune responses against the	14
currently being tested in	14
influenza a virus vaccine	14
had a score of	14
influenza a virus in	14
access article distributed under	14
the first licensed dengue	14
of dengue virus infection	14
a dna vaccine for	14
to induce a strong	14
of the central nervous	14
bovine respiratory syncytial virus	14
can be prevented by	14
in the generation of	14
the efficacy and safety	14
years of age in	14
to enhance the immune	14
avian h n influenza	14
as a model for	14
of an immune response	14
as well as by	14
vaccine with or without	14
the next generation of	14
licensed for human use	14
as a part of	14
of the vaccine with	14
neutralizing antibodies in mice	14
of the designed vaccine	14
induction of neutralizing antibodies	14
increases the risk of	14
been shown to reduce	14
of the effects of	14
an immune response to	14
vaccines need to be	14
the vaccine adverse event	14
studies are needed to	14
these findings suggest that	14
in the identification of	14
would need to be	14
protective immune responses to	14
the success of the	14
systemic and mucosal immunity	14
both humoral and cell	14
efforts have been made	14
immune system of the	14
used as an adjuvant	14
induction of a protective	14
in north america and	14
increase the immunogenicity of	14
induce protective immunity in	14
antibody response to the	14
daily risk of infection	14
adverse events following immunization	14
us centers for disease	14
the bill melinda gates	14
from animals to humans	14
is the case for	14
the formation of a	14
in the last years	14
a and b viruses	14
based on the use	14
of a protective immune	14
in an attempt to	14
was associated with a	14
both mucosal and systemic	14
research is needed to	14
not be able to	14
development of an inactivated	14
may lead to the	14
case fatality rate of	14
than that of the	14
a randomised controlled trial	14
to reduce the risk	14
to the ace receptor	14
over the last years	14
influenza vaccination in the	14
adaptive immune responses to	14
are in clinical trials	14
q fraction of people	14
after the onset of	14
strain of vaccinia virus	14
for disease prevention and	14
is known to be	14
in a clinical trial	14
diphtheria and tetanus toxoids	14
for the study of	14
vaccines have been used	14
in a phase iii	14
attenuated tetravalent dengue vaccine	14
an immune response against	14
vaccines have been shown	14
we would like to	14
a randomized clinical trial	14
are known to be	14
and the induction of	14
inactivated and live attenuated	14
histocompatibility complex class i	14
in relation to the	14
in the majority of	14
is more likely to	14
identification and characterization of	14
in mice and ferrets	14
a significant impact on	14
be safe and effective	14
with the infected living	14
an increased risk for	14
should not be used	14
the world health assembly	14
developed and developing countries	14
the department of health	14
the efficacy of vaccines	14
to induce a protective	14
it is well known	14
article distributed under the	14
a number of vaccines	14
based vaccines have been	14
to be vaccinated against	14
a lethal dose of	14
in animal models and	14
a dna vaccine against	13
increase in the number	13
disease is caused by	13
this work was supported	13
and shown to be	13
in the control group	13
of the st century	13
in spite of the	13
the identification of a	13
induce an immune response	13
has been demonstrated to	13
viraemia of carp virus	13
in the ipv du	13
b cell and t	13
upper and lower respiratory	13
of the disease is	13
may or may not	13
phase ii clinical trials	13
to influenza a virus	13
united states department of	13
of porcine reproductive and	13
brsv and bpi v	13
reducing the risk of	13
in the northern hemisphere	13
countries in the region	13
of a number of	13
of neutralizing antibody responses	13
develop a vaccine against	13
the t cell response	13
the total number of	13
a server for prediction	13
for which there is	13
live attenuated vaccines are	13
cell and t cell	13
and can be used	13
in vivo and in	13
of a future covid	13
influenza h n virus	13
expressing the s protein	13
for use as a	13
of the placebo group	13
administration of the vaccine	13
of porcine epidemic diarrhea	13
be taken into consideration	13
in the area of	13
strong humoral and cellular	13
at increased risk for	13
and clinical development of	13
the time of vaccination	13
such as dendritic cells	13
immunopathology on challenge with	13
of the effect of	13
vaccines for infectious diseases	13
major cause of morbidity	13
the eradication of smallpox	13
was found to have	13
protective immunity against lethal	13
vivo and in vitro	13
which is responsible for	13
on the nature of	13
in a way that	13
in vaccine development and	13
against h n and	13
as an oral vaccine	13
an h n virus	13
by binding to the	13
b virus surface antigen	13
in the fight against	13
as a consequence of	13
encoding the s protein	13
of the vaccine to	13
it has been proposed	13
on the type of	13
of protective immune responses	13
a robust immune response	13
can be engineered to	13
preventable diseases in the	13
clinical trial of a	13
development of effective vaccines	13
diseases in the united	13
hepatitis b vaccine in	13
and approved the final	13
willingness to be vaccinated	13
north america and europe	13
the immune system is	13
have been successfully used	13
the vaccination guidelines group	13
respiratory syncytial virus in	13
these data suggest that	13
the case of a	13
the sequence of the	13
hepatitis b virus surface	13
progress in the development	13
immunization practices advisory committee	13
an immune response in	13
the cost of the	13
for prediction of protective	13
due to the high	13
coronavirus from patients with	13
construction and characterization of	13
and it has been	13
valent pneumococcal conjugate vaccine	13
of modified vaccinia virus	13
centre for disease prevention	13
of the most common	13
of a candidate vaccine	13
and the immune response	13
the structural proteins of	13
the human immunodeficiency virus	13
between and years of	13
to be due to	13
a significant reduction in	13
reactogenicity and immunogenicity of	13
of this approach is	13
than months of age	13
respiratory syndrome coronavirus infection	13
to suppress the pandemic	13
is the development of	13
mrna vaccine against sars	13
into the host genome	13
as a vaccine candidate	13
per cent of respondents	13
to the h n	13
in healthy adults in	13
syndrome induced by adjuvants	13
the early stages of	13
of inactivated influenza vaccine	13
subtypes of influenza a	13
of a safe and	13
server for prediction of	13
or absence of r	13
improve the efficacy of	13
be vaccinated against covid	13
as vaccine delivery systems	13
protection against a lethal	13
has been identified as	13
the physicochemical properties of	13
the potential impact of	13
the mechanisms by which	13
for hepatitis b virus	13
and evaluation of a	13
in such a way	13
this approach has been	13
clinical signs of disease	13
will be necessary to	13
the risk of infection	13
in the response to	13
american association of feline	13
to respiratory syncytial virus	13
induce high levels of	13
t cell responses against	13
in their ability to	13
was used as a	13
that the use of	13
were shown to be	13
a consequence of the	13
complete genome sequence of	13
with a focus on	13
the first months of	13
of the immunogenicity of	13
antigens and subunit vaccines	13
united states of america	13
the form of a	13
novel coronavirus from patients	13
bovine parainfluenza virus type	13
need to be considered	13
human parainfluenza virus type	13
immunity to the vaccine	13
the establishment of a	13
the tertiary structure of	13
of safety and efficacy	13
the rapid development of	13
the large number of	13
the availability of a	13
the ultimate goal of	13
of influenza virus infection	13
and the level of	13
and the possibility of	13
was detected in the	13
the upper and lower	13
evaluate the efficacy of	13
of an h n	13
in all age groups	13
in a recent study	13
for the management of	13
studies have been conducted	13
of the virus into	13
it is also important	13
in the st century	13
to the activation of	13
it remains to be	13
is the fact that	13
of an effective vaccine	13
of japanese encephalitis virus	13
with pneumonia in china	12
to the host cell	12
vaccination of mice with	12
vaccine has not been	12
similar to those of	12
safety and immunogenicity in	12
vaccine virus selection process	12
of the immunization practices	12
respiratory syncytial virus and	12
accelerate the development of	12
macrophages and dendritic cells	12
live attenuated or inactivated	12
vaccines as well as	12
which is based on	12
in a cohort of	12
found to be associated	12
in order to be	12
the development of mucosal	12
neutralizing antibodies against the	12
the antigen of interest	12
of the risk of	12
a leading cause of	12
a cd t cell	12
months of age and	12
a great deal of	12
to improve the immunogenicity	12
an effective vaccine against	12
the number of deaths	12
for the preparation of	12
use of reverse genetics	12
the secondary structure of	12
vaccine in older adults	12
it may be that	12
may be necessary to	12
the potential use of	12
is also important to	12
antibody response in mice	12
mhc class ii molecules	12
to an increase in	12
preliminary report of a	12
immunization with modified vaccinia	12
the production of antibodies	12
in patients with covid	12
high morbidity and mortality	12
improve the immunogenicity of	12
with a variety of	12
trivalent inactivated influenza vaccine	12
vaccine was licensed in	12
on the acceptability of	12
in part due to	12
be taken into account	12
are listed in table	12
may be required to	12
single dose of the	12
immune responses elicited by	12
use in the united	12
of influenza vaccination in	12
it is unlikely that	12
pandemic influenza a h	12
is mediated by the	12
patients with pneumonia in	12
to enhance immune responses	12
there are more than	12
the virus and the	12
was used for the	12
a single immunization with	12
influenza vaccine in healthy	12
the global vaccine action	12
and h n viruses	12
no conflicts of interest	12
in the past decade	12
a specific immune response	12
association of feline practitioners	12
safety and effectiveness of	12
that is able to	12
the seasonal influenza vaccine	12
in the long term	12
used to determine the	12
viremia of carp virus	12
need to be addressed	12
in clinical trials and	12
structure of the vaccine	12
is a highly contagious	12
and in some cases	12
not included in the	12
of human papillomavirus type	12
risk of severe disease	12
the immunization practices advisory	12
purified inactivated sars vaccine	12
the mechanisms of action	12
and is associated with	12
and reducing contact with	12
in a study of	12
of this review is	12
and months of age	12
of innate and adaptive	12
recommendation is to use	12
to be involved in	12
have been observed in	12
the risk of the	12
and control of influenza	12
the s protein is	12
the extent to which	12
a vaccine clinical trial	12
for the next pandemic	12
clinical trials have been	12
database and analysis resource	12
of the phs act	12
due to the presence	12
the vaccine can be	12
the gene of interest	12
development of a sars	12
of the novel coronavirus	12
the mode of action	12
was also observed in	12
the level of the	12
recommendations of the immunization	12
lead to the development	12
by a combination of	12
cd t cells are	12
there is a risk	12
note springer nature remains	12
of classical swine fever	12
response to the antigen	12
this has led to	12
igg and igg a	12
children in the united	12
of the virus is	12
plasmodium falciparum circumsporozoite protein	12
immune response of the	12
ebola outbreak in west	12
current status and future	12
in a short time	12
of the viral envelope	12
clinical development of a	12
vaccine in the elderly	12
and have been used	12
risks and benefits of	12
disease in the united	12
the current status of	12
against canine visceral leishmaniasis	12
to better understand the	12
modified live virus vaccine	12
in humans and animals	12
by a number of	12
there has been an	12
been made in the	12
expression of a foreign	12
also been used to	12
and t cell epitopes	12
the context of a	12
by respiratory syncytial virus	12
of mhc class i	12
i ii clinical trial	12
humoral immune responses in	12
identification of a novel	12
of age and older	12
of different types of	12
immune responses and protection	12
the induction of immune	12
risk factors associated with	12
is well known that	12
and a variety of	12
tolerability and immunogenicity of	12
is unlikely to be	12
should be given to	12
people aged years and	12
also referred to as	12
as the use of	12
in preclinical and clinical	12
the time of first	12
in the small intestine	12
ha of h n	12
there are a number	12
t cell immune responses	12
was estimated to be	12
for emerging infectious diseases	12
until the end of	12
the effect of the	12
have been tested for	12
rest of the world	12
play a significant role	12
considered to be a	12
the study of the	12
a vaccine that is	12
rational design of vaccines	12
local and systemic reactions	12
is the most effective	12
the major histocompatibility complex	12
the united states of	12
the immune system has	12
an incubation period of	12
t and b cell	12
use of live attenuated	12
of the same vaccine	12
in light of the	12
provide an overview of	12
to overcome the limitations	12
development and use of	12
are referred to as	12
as well as for	12
chitosan and its derivatives	12
of reversion to virulence	12
prevent the spread of	12
immune response to a	12
vaccines have been tested	12
it may be necessary	12
vaccination in the united	12
on the immunogenicity of	12
by antigen presenting cells	12
is to use a	12
of universal influenza vaccines	12
tested in a phase	12
of balb c mice	12
to improve the efficacy	12
of the host cell	12
are a number of	12
the safety profile of	12
respiratory syndrome coronavirus in	12
a h n influenza	12
the choice of the	12
can be recognized by	12
have also been reported	12
are involved in the	12
cytokines such as il	12
being tested in clinical	12
and the production of	12
an important cause of	12
are based on the	12
immunogenicity of dna vaccines	12
lower than that of	12
of cellular and humoral	12
to their ability to	12
to the absence of	12
may contribute to the	12
influenza a virus vaccines	12
the immunogenicity and safety	12
surface antigen in transgenic	12
a humoral immune response	11
can be attributed to	11
strategies in puppies and	11
may not be the	11
their ability to induce	11
the group that received	11
in the us and	11
for some of the	11
a major public health	11
some of the most	11
hundreds of thousands of	11
will be important to	11
is similar to that	11
a decrease in the	11
due to the fact	11
when it comes to	11
of a live attenuated	11
a phase ii study	11
the past two decades	11
the identification of new	11
the level of immunity	11
vaccines are able to	11
the current state of	11
a case fatality rate	11
need to be overcome	11
for h n influenza	11
against west nile virus	11
the only way to	11
may be able to	11
and lower respiratory tract	11
the present study was	11
have been detected in	11
in the developed world	11
of the foreign gene	11
authors would like to	11
the cd t cell	11
the two vaccine groups	11
a small number of	11
the influenza a virus	11
of the new vaccine	11
this vaccine has been	11
a wide array of	11
evaluated in clinical trials	11
n influenza a virus	11
a number of different	11
in phase i clinical	11
in animals and humans	11
a delivery system for	11
an adequate immune response	11
morbidity and mortality weekly	11
in the european union	11
to respond to the	11
of hepatitis b vaccine	11
are the most common	11
vaccine was shown to	11
views on the acceptability	11
of the world health	11
even in the absence	11
have focused on the	11
see chapter e vaccine	11
the hepatitis b vaccine	11
remains to be seen	11
induction of mucosal immunity	11
safe and effective in	11
induce a protective immune	11
correlates of protection for	11
designed for use in	11
with the introduction of	11
delivery of plasmid dna	11
activation of the immune	11
with a history of	11
could be attributed to	11
form of the disease	11
protective levels of antibody	11
for the protection of	11
advisory group of experts	11
between and weeks of	11
of the impact of	11
adults aged years or	11
and humoral immune response	11
with the risk of	11
the cellular immune response	11
the prevention of influenza	11
if the vaccine is	11
of humoral and cellular	11
the baculovirus expression system	11
to a variety of	11
in this article are	11
also found to be	11
countries such as the	11
of vaccines against infectious	11
of h n viruses	11
in embryonated chicken eggs	11
cell responses induced by	11
proportion of the population	11
this version posted may	11
direct contact with infected	11
of cellular immune responses	11
is not included in	11
in the same way	11
and cellular immune response	11
potential conflict of interest	11
mode of action of	11
these vaccines have been	11
at a time when	11
dna vaccine encoding the	11
and treatment of influenza	11
it is anticipated that	11
as a single dose	11
of the m protein	11
of the humoral immune	11
have been approved for	11
immunization against hepatitis b	11
adults years of age	11
we are grateful to	11
it is not clear	11
the adjuvant activity of	11
the national vaccine advisory	11
an example of a	11
one of the greatest	11
this is due to	11
grand average of hydropathicity	11
the public health service	11
for use in cats	11
igg antibodies in serum	11
responses as well as	11
response to the virus	11
gene transfer into mouse	11
of the sars coronavirus	11
by cd t cells	11
to a lesser extent	11
tumour antigens and subunit	11
vaccination strategies in puppies	11
an mrna vaccine against	11
immune responses to dna	11
for which vaccines are	11
of the role of	11
and colleagues at the	11
of h n vaccine	11
the production of viral	11
more than of the	11
has been reported in	11
severity of the disease	11
the safety of vaccines	11
state of the art	11
the degree to which	11
vaccine for prevention of	11
human and veterinary vaccines	11
disease caused by the	11
used to predict the	11
dna vaccines can be	11
like particle vaccine in	11
of total soluble protein	11
doses of the vaccine	11
a small fraction of	11
and the fact that	11
the vp capsid protein	11
was the first to	11
the acceptability of a	11
the time of writing	11
are unlikely to be	11
implications for vaccine design	11
and severe acute respiratory	11
section of the phs	11
a study of the	11
in the following sections	11
adaptive immunity to the	11
a phase iii clinical	11
from the perspective of	11
immunodefi ciency virus type	11
the disease caused by	11
t cell response to	11
pandemic influenza vaccine in	11
get vaccinated against covid	11
inactivated severe acute respiratory	11
immune system and the	11
is currently being tested	11
white spot syndrome virus	11
will be required to	11
for each of the	11
threats to global health	11
read and approved the	11
mice and guinea pigs	11
in the last decade	11
a h n vaccine	11
as a potential vaccine	11
the development of live	11
and the availability of	11
in combination with the	11
of vaccination is to	11
and a z score	11
in a phase ii	11
of mucosal and systemic	11
it has been estimated	11
efficacy of a vaccine	11
reducing contact with the	11
with the advent of	11
mice and nonhuman primates	11
efficacy of dna vaccines	11
of th and th	11
have proven to be	11
to be an effective	11
of canine distemper virus	11
the first line of	11
cytotoxic t cell response	11
is important to understand	11
most likely to be	11
evaluate the safety and	11
have been developed that	11
vaccines are administered to	11
the expression level of	11
to be tested in	11
and systemic antibody responses	11
neutralizing antibody responses in	11
eliciting an immune response	11
is similar to the	11
by the innate immune	11
on the day of	11
of the safety of	11
with live or inactivated	11
the united states department	11
morbidity and mortality from	11
cytotoxic t lymphocyte responses	11
acceptability of a future	11
was also found to	11
immunity to the antigen	11
with the ability to	11
disease virus as a	11
are currently being tested	11
infectious diseases in the	11
more than half of	11
of vaccines and the	11
alliance for vaccines and	11
of the russian federation	11
protective immune responses in	11
in the current study	11
and has been used	11
the h n subtype	11
reduced the incidence of	11
against rift valley fever	11
in puppies and kittens	11
and mortality weekly report	11
may be associated with	11
the vaccine in the	11
induce a strong immune	11
drug and gene delivery	11
well as in the	11
the acute phase of	11
a number of vaccine	11
innate immune response to	11
referred to as the	11
from the h n	11
to develop vaccines against	11
which can be used	11
vaccines are being developed	11
of the infectious agent	11
this review is to	11
children and young adults	11
pathogenic h n avian	11
to be highly effective	11
of the lack of	11
in the placebo group	11
to cause disease in	11
work was supported by	11
challenge with live virus	11
are at high risk	11
an acceptable safety profile	11
a z score of	11
infected from vaccinated animals	11
expression of hepatitis b	11
in a vaccine clinical	11
reduce the incidence of	11
to play a role	11
during the h n	11
of one or more	11
development of safe and	11
of a vaccine in	11
into the genome of	11
the prevention of infectious	11
to influenza virus infection	11
the course of the	11
of safety and immunogenicity	11
and tetanus toxoids and	11
may play a role	11
was found that the	11
by serial passage in	11
has resulted in a	11
the use of plant	11
in the blood and	11
has been proposed that	11
vaccine has been developed	11
have been made in	11
vaccines in the united	11
with respiratory syncytial virus	11
mucosal immune responses in	11
of the chadox ncov	11
transfer into mouse muscle	10
reduce the burden of	10
vaccine protects mice against	10
pneumonia in rhesus macaques	10
been used in the	10
are more susceptible to	10
vaccine should be administered	10
curl new delhi virus	10
infection as well as	10
it is critical to	10
development and testing of	10
for the development and	10
of avian influenza a	10
immunogenicity of a dna	10
of inactivated poliovirus vaccine	10
to get vaccinated against	10
a comparison of the	10
there is currently no	10
treatment of influenza in	10
under a creative commons	10
been approved for use	10
activation of the innate	10
as shown in table	10
java codon adaptation tool	10
give appropriate credit to	10
in an animal model	10
humoral immune responses to	10
burden of infectious diseases	10
a result of these	10
after the second dose	10
the development of improved	10
the potential role of	10
hepatitis b core antigen	10
the vaccine with the	10
use of this vaccine	10
medical and public health	10
homologous and heterologous h	10
emerging and neglected diseases	10
tomato leaf curl new	10
class i and ii	10
has proven to be	10
the global alliance for	10
the scope of this	10
followed by boosting with	10
the amino acid sequence	10
in a manner that	10
a part of the	10
small animal veterinary association	10
and acellular pertussis vaccine	10
and tumor necrosis factor	10
there may be a	10
as a vaccine for	10
approved the final manuscript	10
viral vectors have been	10
in the sera of	10
humoral immune responses against	10
of porcine circovirus type	10
the risk of vaccine	10
patients infected with novel	10
common mucosal immune system	10
strategic advisory group of	10
protection against lethal challenge	10
influenza vaccine virus selection	10
credit to the original	10
in the search for	10
antibody and t cell	10
that could be used	10
weeks after the second	10
the thymidine kinase gene	10
likely to reject a	10
to the creative commons	10
syndrome is associated with	10
been attributed to the	10
immune responses that are	10
if a vaccine is	10
on the induction of	10
cells and t cells	10
into mouse muscle in	10
of nucleic acid vaccines	10
influenza vaccine in adults	10
a phase iii study	10
a number of other	10
the risk of adverse	10
on the one hand	10
and has been shown	10
the difference between the	10
induced by the vaccine	10
lower respiratory tract infection	10
data needed to support	10
on taxonomy of viruses	10
to the development and	10
mhc class i molecules	10
mmr vaccine and autism	10
and the impact of	10
upper respiratory tract infections	10
have no competing interests	10
this strategy has been	10
arms of the immune	10
protective efficacy of the	10
correlates of protection are	10
that a single dose	10
the democratic republic of	10
as a vaccine against	10
there is no vaccine	10
can be detected in	10
international committee on taxonomy	10
immune responses to the	10
would be required to	10
to confer protection against	10
has been tested in	10
use of viral vectors	10
in a timely manner	10
play a crucial role	10
of a single dose	10
assess the safety and	10
structure and function of	10
californica nuclear polyhedrosis virus	10
direct gene transfer into	10
infected with novel coronavirus	10
there is some evidence	10
cd t cell epitopes	10
in the lower respiratory	10
of a universal vaccine	10
a link to the	10
influenza virus h n	10
leaf curl new delhi	10
a swine h n	10
development of more effective	10
the next influenza pandemic	10
and is expected to	10
it is not known	10
at the expense of	10
transmission of zika virus	10
time of first vaccination	10
the fraction of people	10
the origin of the	10
a west nile virus	10
have also been shown	10
may be used in	10
single dose of a	10
to the original author	10
to develop an effective	10
of adverse events following	10
before the onset of	10
mice immunized with a	10
influenza and respiratory syncytial	10
not appear to be	10
of infectious diseases and	10
vaccine was developed by	10
an example is the	10
has been used as	10
to take the vaccine	10
immune response against a	10
the west african ebola	10
significant increase in the	10
plasmid dna encoding the	10
pandemic h n virus	10
the us centers for	10
the etiologic agent of	10
such as the use	10
public health problem in	10
remains to be determined	10
have been demonstrated to	10
from the injection site	10
the vaccines for children	10
of t cell responses	10
are taken up by	10
overcome the limitations of	10
genome sequence of the	10
will continue to be	10
infectious hematopoietic necrosis virus	10
the american association of	10
for use in children	10
with the potential for	10
the combined vector vaccine	10
immunity to the vector	10
been used to develop	10
hundreds of millions of	10
provide a link to	10
been shown to have	10
for safety and efficacy	10
need for a vaccine	10
it may be possible	10
the second dose of	10
clinical features of patients	10
identification of potential vaccine	10
of pattern recognition receptors	10
mouse muscle in vivo	10
was based on the	10
associated with a new	10
and indicate if changes	10
and risk factors for	10
indicate if changes were	10
in addition to these	10
report of a phase	10
the vaccine is safe	10
a good safety profile	10
the vaccine safety datalink	10
mice were immunized with	10
of influenza vaccination of	10
vaccines for infectious disease	10
and emerging infectious diseases	10
in clinical trials for	10
the highest level of	10
of the emergence of	10
on the safety of	10
provided complete protection against	10
was used to predict	10
in silico prediction of	10
the ability of a	10
of antigen and adjuvant	10
to the onset of	10
a variety of other	10
development of a novel	10
efforts to develop a	10
the evaluation of the	10
and reproduction in any	10
in the vaccine and	10
in the immune response	10
of type i ifn	10
doses of influenza vaccine	10
cell responses to the	10
as a possible cause	10
to the vaccine antigen	10
in the range of	10
of the severe acute	10
is the risk of	10
candidates in clinical trials	10
which are able to	10
the presence of antibodies	10
levels of neutralizing antibody	10
code of federal regulations	10
and cytotoxic t lymphocyte	10
in a range of	10
development of vaccines to	10
vaccination of dogs and	10
epitope vaccine candidate against	10
for the purpose of	10
the ha and na	10
secondary structure of the	10
of the gastrointestinal tract	10
the absence of the	10
attempts have been made	10
ability to respond to	10
features of patients infected	10
with plasmid dna encoding	10
control of infectious diseases	10
in the genome of	10
vaccine in healthy children	10
safety of a recombinant	10
be used to develop	10
mhc class i pathway	10
h n virus was	10
the production of recombinant	10
of the vaccine candidate	10
autographa californica nuclear polyhedrosis	10
as a correlate of	10
threat to human health	10
of the antigen in	10
years of age with	10
considered to be the	10
preclinical and clinical studies	10
the risks and benefits	10
h n vaccine in	10
and public health professionals	10
one or more of	10
for vaccines and immunization	10
because of the lack	10
to accelerate the development	10
a preliminary report of	10
intranasal immunization of mice	10
it is not possible	10
h n infection in	10
a new era in	10
recombinant vaccinia virus expressing	10
the development of safe	10
in the mva genome	10
of a vaccine that	10
for a vaccine to	10
has been approved for	10
virus infection in mice	10
to protect against the	10
virus infection in the	10
are a group of	10
the etiological agent of	10
the protective effect of	10
specific immune responses in	10
approved for human use	10
is expected to be	10
against highly pathogenic avian	10
within the context of	10
and live attenuated influenza	10
tumor necrosis factor alpha	10
the immune response is	10
you give appropriate credit	10
increase in the incidence	10
the vaccine construct is	10
stability of the vaccine	10
mice against a lethal	10
by attenuated vaccinia virus	10
clinical data needed to	10
the first time in	10
with influenza a virus	10
hemorrhagic fever with renal	10
amino acid sequence of	10
antibody and cellular immune	10
first line of defense	10
i clinical trial of	10
appropriate credit to the	10
to the draining lymph	10
the severity of disease	10
in collaboration with the	10
with two doses of	10
in a phase clinical	10
the search for a	10
an h n influenza	10
if changes were made	10
diagnosis and treatment of	10
animal care and use	10
antibody responses in mice	10
to produce a vaccine	10
intent to be vaccinated	10
at to weeks of	10
produced in transgenic plants	10
have been developed in	10
of a sars vaccine	10
respiratory syndrome is associated	10
the increasing number of	10
two doses of the	10
between cases and controls	10
is generally not recommended	10
treatment of influenza a	10
a portion of the	10
the number of animals	10
reproduction in any medium	10
link to the creative	10
could be due to	10
was used as an	10
in the management of	10
a creative commons attribution	10
younger than years of	10
children years of age	10
influenza virus infection by	10
who have recovered from	10
with novel coronavirus in	10
vaccine in the presence	10
of the vaccine strain	10
between the ages of	10
to make the vaccine	10
it will be important	10
b cell responses in	10
are some of the	10
the risk of transmission	10
reduce the number of	10
to the world health	10
committee on taxonomy of	10
of the influenza vaccine	10
fever with renal syndrome	10
are required for the	10
and highly immunogenic in	10
the development of universal	10
is taken up by	10
to draining lymph nodes	10
physicochemical properties of the	10
in england and wales	10
the effectiveness of a	10
to contribute to the	10
of the most promising	10
live or inactivated ibv	10
and stability of the	10
for the vaccination of	10
licensed under a creative	10
are similar to those	10
with the host cell	10
the expression of a	10
are being developed for	10
the united states during	10
a range of vaccine	10
cells as well as	10
has been proposed as	10
for a new vaccine	10
a recombinant vaccinia virus	10
global alliance for vaccines	10
efficacy of a recombinant	10
been proposed as a	10
the binding affinity of	10
after vaccination with a	10
immunogenicity of the chadox	10
of the potential for	10
the united states has	10
health care workers and	10
expressed by attenuated vaccinia	10
global burden of disease	10
designed to protect against	10
and there is a	10
of vaccines against emerging	10
robust humoral and cellular	10
newcastle disease virus as	10
has also been observed	10
for at least years	10
vaccine was found to	10
and rift valley fever	10
the most promising vaccine	10
incidence of adverse events	9
view a copy of	9
would have to be	9
that there was no	9
is an example of	9
may be asymptomatic or	9
in the lymph nodes	9
the terms and conditions	9
the second and third	9
in order to evaluate	9
benefits and risks of	9
vaccine against novel coronavirus	9
was reported to be	9
contact with dead bodies	9
it is noteworthy that	9
control the spread of	9
in view of the	9
participate in a covid	9
display efficiency in in	9
to be used to	9
presentation to cd t	9
as a vector for	9
vaccines at pandemic speed	9
vaccine against severe acute	9
shown to be immunogenic	9
a credit line to	9
is safe and effective	9
responses elicited by a	9
into the pet a	9
with a new coronavirus	9
the gene encoding the	9
immune response elicited by	9
upper respiratory tract infection	9
are expected to be	9
injection of dna encoding	9
vaccine administered to infants	9
the united arab emirates	9
and the vaccine was	9
vaccine candidates have been	9
in terms of safety	9
enhanced respiratory syncytial virus	9
silico prediction of allergens	9
compendium of animal rabies	9
material is not included	9
within a short period	9
otherwise in a credit	9
for drug and gene	9
the duration of immunity	9
for the purposes of	9
it is unclear whether	9
against lethal challenge with	9
the burden of infectious	9
and at the same	9
to the plasma membrane	9
development of mucosal vaccines	9
is the case with	9
are most likely to	9
a new coronavirus of	9
an important component of	9
it is not yet	9
of neutralizing antibodies against	9
upper respiratory tract disease	9
be one of the	9
can serve as a	9
pathogenic h n virus	9
also known as the	9
in most of the	9
vaccine was safe and	9
the wild type virus	9
the ebola outbreak in	9
need to be taken	9
towards the development of	9
this article are included	9
is found to be	9
induced higher levels of	9
in the vaccine development	9
public health impact of	9
for the formulation of	9
infection caused by the	9
in the time of	9
has been estimated that	9
phase iii efficacy trials	9
in an endemic area	9
zika virus dna vaccine	9
vaccine effectiveness and coverage	9
may be possible to	9
to its ability to	9
it was demonstrated that	9
development of universal influenza	9
in vitro systems has	9
was one of the	9
there is evidence that	9
cluster had a score	9
rabies prevention and control	9
of potential vaccine targets	9
is a member of	9
the type of immune	9
has been developed to	9
vaccines in developing countries	9